IndraLab
Statements
Hydroxychloroquine inhibits viral load. 40 / 40
|
40
eidos
"In early clinical studies , chloroquine and hydroxychloroquine were suggested to reduce viral load and improve clinical outcomes in individuals with COVID-19 ( Gao et al ., 2020 ; Gautret et al ., 2020 ) with an even better effect when combined with azithromycin ( Gautret et al ., 2020 ) ."
eidos
"A recent study suggested that hydroxychloroquine could significantly reduce the viral load [ 7 ] , but it was conducted in outpatients and a recent trial [ 10 ] performed in the ICU failed to demonstrate any benefit of lopinavir / ritonavir on clinical outcomes and viral load reduction ."
eidos
"Preliminary results by Gautret et al. suggest that HCQ 600 mg daily may decrease viral load in nasal swabs [ 54 ] ; furthermore , Gao reports that `` chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of pneumonia , improving lung imaging findings , promoting a virus negative conversion , and shortening the disease course '' [ 55 ] ."
eidos
"In summary , while protease inhibitors may decrease viral burden , inhaled nitric oxide may reduce V / Q mismatch , anticytokine therapy may treat cytokine storm or prevent its progression , and immunomodulators like chloroquine / hydroxychloroquine may inhibit viral replication , RRx-001 may serve as an all-in-one therapy , which improves cardiopulmonary function , decreases viral burden and reduces the systemic inflammatory response ."
| PMC
eidos
"47 These studies , including to date the largest RECOVERY trial , show that at the doses used , CQ or HCQ ( with or without AZM ) is not effective in reduction of viral load , post-exposure prophylaxis , improving survival or reducing the need for respiratory support in hospitalized patients ."
eidos
"40 A pilot observational study from France demonstrated that HCQ reduced viral load in most COVID-19 patients and that its efficacy was enhanced in combination with azithromycin.41 HCQ could be administered early in the COVID-19 course to prevent the spread of the infection or in the late stages during the cytokine storm ."
| PMC
eidos
"Overall evaluation of the available evidence ( Table 1 ) shows that at the doses used , CQ or HCQ ( with or without AZM ) is not effective in reduction of viral load , post-exposure prophylaxis , improving survival or reducing the need for respiratory support in hospitalized patients ."
eidos
"CQ and HCQ may interfere with virus replication at the early stages of infection or increasing endosome-mediated pH at the viral entry / cell fusion , as well as post-translational modification of the glycosylation of cellular receptors of SARS-CoV-2.6 Along with this , Savarino et al suggested that CQ may reduce the level of inflammatory cytokines and could ameliorate acute respiratory distress syndrome.11 Recent preliminary clinical studies suggested that CQ and HCQ may be able to lower the COVID-19 viral load and reduce the duration of viremia ."